Cardiometabolic & kidneySecondary analysis
The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study
- Secondary analysis of the FIELD randomised trial
Authors' conclusion
Higher baseline HP levels were associated with a higher CVD risk, especially in participants with HP 1-1 phenotype. A lower CVD risk is found only in Type 2 diabetes participants with both the HP 1-1 phenotype and low baseline HP levels. Fenofibrate benefits on CVD risk reduction did not differ by HP levels or phenotype.
Study context
- Population
- T2DM participants of the Fenofibrate Intervention and Event Lowering in Diabetes trial
- Participants
- 8,047 participants
- Comparison
- Tertile 3 vs Tertile 1
- Primary endpoint
- New on-trial total CVD events
- Follow-up
- 5 years
Primary result
As reported in the abstract
Total CVD events by baseline HP level:
- Placebo group
- N = 4030
Hazard ratio
1.30
95% CI 1.02–1.66
P = 0.035
Tertile 3 vs Tertile 1
HR 1.30 (95% CI 1.02–1.66); P = 0.035
- Association driven by participants with haptoglobin (HP) 1-1 phenotype
- P for interaction = 0.011
Further findings
Cardiovascular disease (CVD) risk by HP level tertile and HP phenotype
- Lowest baseline HP tertile with HP 1-1 phenotype tended to have the lowest CVD risk; risk similar in others regardless of HP phenotype and levels
Fenofibrate benefit on total CVD events by HP phenotype, baseline HP tertile, or tertile of HP change during run-in
- Fenofibrate benefit did not differ significantly by HP phenotypes, baseline HP level tertiles or tertiles of HP change
Original publication
The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study. Eur J Prev Cardiol. Published 11 September 2025. doi:10.1093/eurjpc/zwaf562
Summarised from the published abstract; every number is checked against it